Grand Venture Technology embarks on the next chapter of global growth as Aalberts completes the privatisation of the company

SINGAPORE, Oct. 31, 2025 /PRNewswire/ — Novo Tellus, a leading private equity fund focused on building industrial and technology companies, is pleased to announce the successful completion of its investment in Grand Venture Technology (“GVT” or the “Company”). 

Novo Tellus inaugurated its partnership with GVT in March 2021, when it invested in S$ 30 million at S$ 0.33/share to help fund a significant build-out of GVT’s manufacturing capacity and capabilities.

Over the last 4 years, Novo Tellus has worked closely with GVT to help grow the company’s capabilities, customers, vertical industries, capacity and productivity resulting in significant earnings and equity growth.

In July 2025, GVT announced an offer by global manufacturing leader Aalberts Advanced Mechatronics to acquire the company at a S$ 0.94/share.  The transaction was closed on 27 October 2025, marking the conclusion of a successful partnership between Novo Tellus and Grand Venture Technology.

Reflecting on the transformative growth at GVT over the last 4 years, CEO Julian Ng said, “we’re proud of what our management team accomplished in partnership with Novo Tellus, and with the support of our strategic customers and dedicated employees.

In the last 4 years, GVT has:

• Grown into a leading manufacturing supplier for top global semiconductor equipment companies. We built a new factory in Penang, grew specialised manufacturing capabilities, and worked tirelessly with our customers to help them push the leading edge of semiconductor manufacturing today. One highlight of this effort was winning the “Best Supplier Award Recognition” from one of our strategic customers, LAM Research.
• Completed 3 successful M&A acquisitions in Singapore, Malaysia and China to accelerate the buildout of our talent, capabilities and scale for our customers.
• Grown our investor relations program and attracted new capital and support from global blue-chip asset managers.

We will miss working with our trusted partners at Novo Tellus, but look forward to being a meaningful part of Aalberts to advance their global manufacturing business successfully in Asia“.

“We’ve been privileged to have worked with the talented leadership at Grand Venture Technology”, said Loke Wai San, Managing Partner of Novo Tellus, adding that “although we are proud to have been partners in such transformative growth, we are grateful to Executive Deputy Chairman Ricky Lee, CEO Julian Ng, and all the leaders and employees of GVT for their relentless efforts to realise an ambitious vision of GVT’s future in the last few years.

We thought it appropriate this year that Julian Ng and Robby Sucipto won the ‘CEO of the Year’ and ‘CFO of the Year’ awards respectively at the Singapore Corporate Awards 2025, a worthy recognition of their enormous accomplishments in the last few years.

Grand Venture Technology embodies the Novo Tellus aspiration to build lasting businesses, and we hope our stewardship has created the foundations and momentum for lasting growth as GVT flourishes under the ownership of Aalberts NV going forward”.

About Grand Venture Technology

Founded in 2012, GVT is a fast-growing and trusted solutions and services provider for the manufacture of complex precision machining, sheet metal components and mechatronics modules. Its manufacturing plants in Singapore, Penang and Johor (Malaysia), and Suzhou (China) are backed by the latest automated manufacturing technologies, Class 10,000 cleanroom facilities and a certified quality management system. The Group’s highly experienced and dedicated team of engineering talent serves a strong global network of established partners and suppliers with a wide range of engineering, assembly, testing and product life cycle management solutions. GVT’s portfolio of customers hail from the semiconductor, electronics, analytical life sciences, aerospace, medical and industrial automation industries, and represent some of the largest OEMs in their respective markets. To learn more about Grand Venture Technology, visit gvt.com.sg

About Novo Tellus

Novo Tellus is a private equity firm focused on building lasting technology and industrial companies in Southeast Asia. The firm is distinguished by its deep insight into shifts in the global technology ecosystem, and by its active and empathic partnerships with management teams to build lasting businesses and superior investment returns.

To learn more about partnering with Novo Tellus, visit novotellus.com

DUBAI, UAE, Oct. 31, 2025 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, is thrilled to announce the launch of its year-end edition of the Daily Treasure Hunt: The Ultimate Gold Mine. The event marks the grand finale of Bybit’s 2025 reward campaigns, offering users an opportunity to unearth legendary digital treasures through trading and earning activities.

Event Schedule

• Pre-registration Opens:October 31, 2025, at 10:00 a.m. UTC
• Main Event Period:November 7, 2025, at 10:00 a.m. UTC – December 22, 2025, at 9:59 a.m. UTC
• Points Redemption Deadline:December 25, 2025, at 11:59 p.m. UTC

This year’s edition introduces two distinct “tunnels to treasure”—the Trade Task Vein and the Earn Task Vein. The Trade Task Vein allows users to execute trades to earn consistent rewards, while the Earn Task Vein provides a low-risk, accessible way for participants to complete simple tasks and securely grow their points.

At the heart of The Ultimate Gold Mine lies a 300,000 USDT prize pool, distributed through the Points Plaza Exchange and Unlimited Mining Cards. Users can redeem points for a share of the prize pool, scratch unlimited cards for bonus prizes, and uncover “Legendary Finds” including Bitcoin (BTC) rewards of up to $10,000, Boost Coupons, VIP trial passes, and other exclusive bonuses.

Participants’ points will accumulate daily throughout the event, with consistent engagement yielding higher potential rewards. The structure encourages early participation and sustained activity, turning daily efforts into a year-end windfall.

For further information and full terms and conditions, participants may refer to the official event page on Bybit’s website.

Disclaimer
Eligibility requires identity verification, and participation is restricted in certain jurisdictions, including the European Economic Area. Full details, including restrictions and terms of participation, are outlined in the official Terms and Conditions.

#Bybit / #TheCryptoArk

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 70 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit’s Communities and Social Media
Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

NINGBO, China, Oct. 31, 2025 /PRNewswire/ — China Petroleum & Chemical Corporation (HKG: 0386, “Sinopec”) and BASF jointly declared the alignment on the core requirements of carbon footprint accounting methods and reached framework-based mutual recognition of methodologies at the 2025 China International Petroleum and Chemical Conference (CPCIC 2025) hosted from October 22 to 24 in Ningbo.

The consensus, as a corporate example for China’s push to achieve international convergence and mutual recognition of product carbon footprints, marks a key step in low-carbon transformation cooperation between Chinese and German chemical enterprises, taking the lead in establishing mutual trust in product carbon footprint data between Chinese and foreign companies.

Sinopec and BASF jointly commissioned globally leading third-party certification body TÜV Rheinland to conduct a consistency review of both parties’ methodologies. After multiple rounds of evaluations, TÜV Rheinland confirmed that both methodologies comply with international standard ISO14067:2018 and China national standard GB/T 24067–2024, and remain consistent in core elements. A formal consistency statement was issued, leading both parties to a mutual recognition consensus for their product carbon footprint accounting methods.

This move will significantly enhance the comparability and transparency of carbon footprint data across regions and value chains, improve data utilization efficiency, promote coordinated carbon reduction in the industry chain, and contribute to the green, high-quality development of both enterprises and the wider industry.

Sinopec has been at the forefront product carbon footprint management. In 2015, it was China’s first to launch research on product carbon footprint accounting, initially developing a methodological framework for petrochemical products. In 2023, Sinopec achieved China’s first automated carbon footprint accounting for petroleum and chemical products.

In 2024, together with CNPC, CNOOC, PipeChina, and four other enterprises, it initiated and formed China’s first Carbon Footprint Alliance for the energy and chemical industry chain, working collaboratively to reduce emissions across the supply chain.

Since 2021, China has been gradually building a carbon footprint management system and exploring the establishment of standards for products’ full life-cycle carbon footprint, with the goal of preliminarily establishing such a system by 2027 and publishing national product carbon footprint accounting general standards in line with international practice.

The Leading Player in On-Device AI Is Realizing the Physical AI Era While Drawing Wall Street’s Attention

NEW YORK, Oct. 31, 2025 /PRNewswire/ — As AI begins to sustainably generate tangible value, global AI semiconductor innovator DEEPX (CEO Lokwon Kim) today announced it was recently selected as a ‘Sustainable and Responsible AI Innovation Company’ at the MINDS Awards hosted by the World Economic Forum (WEF) on October 29, and was previously invited to the New York Stock Exchange (NYSE) International Day on October 23. At NYSE, DEEPX was chosen as a representative company among 230 privately held technology leaders from 27 countries, as well as taking part in the Closing Bell ceremony and conducting an official interview.

Recognition on two of the world’s most influential stages underscores DEEPX’s central role in the global AI transformation — particularly in addressing the question: ‘Where and how should AI operate?’

DEEPX was founded on CEO Lokwon Kim’s philosophy that “AI is a tool to overcome human ignorance and represents the next leap for human civilization.” This vision extends beyond technology itself to “AI living in the real world, not confined to data centers” — the realization of physical AI.

To achieve this, DEEPX has developed on-device AI semiconductors that execute AI computations directly within devices, without relying on the cloud. This approach simultaneously addresses power consumption, latency, and security challenges — enabling AI infrastructure that operates instantly for real-world applications such as robotics, mobility, smart cities, and industrial automation.

DEEPX’s core technology allows even large AI models with billions of parameters to run at GPU-level performance in an ultra-low-power envelope of just 2 to 5 watts. Independent testing has verified up to 20 times greater power efficiency compared with GPUs and roughly 90 percent lower system cost. Mass-production deployments are already underway at Hyundai Motor Robotics Lab, POSCO DX, Baidu, LGUplus, and other companies.

DEEPX’s growth is inspired by two strands of industrial DNA. Firstly, Arm’s philosophy: Just as Arm led the mobile revolution, DEEPX has achieved ‘AI semiconductors that transcend the limits of power and heat’ through its ultra-low-power NPU technology. The now-famous ‘Butter Test’ — the only chip that didn’t melt butter, showcased at CES and Computex — visually proved DEEPX’s industry-leading power efficiency and thermal control.

Second, Qualcomm’s strategy: Mirroring Qualcomm’s market dominance built on its CDMA foundational patents, DEEPX has assembled a portfolio of more than 400 global patents covering everything from NPU architecture to operational design. According to Forbes, DEEPX currently holds more US-registered NPU patents than other leading players combined.

Leveraging its technological strength and IP strategy, DEEPX began mass production of its first-generation AI chip, the DX-M1, in July 2025. The company is now collaborating with over 50 global partners in robotics, industrial automation, and physical security systems to drive large-scale production and real-world deployment of its on-device AI solutions.

DEEPX is now developing its second-generation NPU based on Samsung’s 2nm process. The chip can execute generative AI models ranging from 2 billion to 10 billion parameters directly on-device while consuming only approximately 5 watts of power. This innovation is expected to reduce data-center dependency by over 80 percent and expand global AI-infrastructure capacity fivefold — without adding new servers. CEO Lokwon Kim continues to lead R&D guided by the belief that AI becomes everyday intelligence only when it operates within industries, cities, homes, and robots.

DEEPX’s dual recognition by the WEF and NYSE carries profound symbolism. The WEF — the center of policy and philosophy — and the NYSE — the center of markets and capital — have together validated the same vision: that AI can evolve in ways that benefit humanity and the planet while remaining economically viable and globally competitive.

This recognition transcends the significance of a typical technology award. It represents a real-world case study proving that ethics, efficiency, and sustainability can coexist through both technology and business.

DEEPX is more than a semiconductor design company. It seeks to change the world not by the speed of technology, but by its direction. Guided by its vision of ‘AI for Everyone and Everywhere,’ DEEPX aims to create a world where AI transcends the limits of technology, society, and resources — thinking and responding autonomously across every aspect of human life and seamlessly integrated into industries, cities, and daily routines.

Learn more at https://deepx.ai/.

Media contact

Ella Lee
lah@deepx.ai

– Aiming to establish af-001 as a new therapeutic option for radioactive iodine (RAI)-naïve patients with differentiated thyroid cancer –

TOKYO, Oct. 31, 2025 /PRNewswire/ — Alpha Fusion Inc. (Headquarters: Chiyoda-ku, Tokyo; CEO: Sunao Fujioka; hereinafter “Alpha Fusion”) today announced the initiation of a company-sponsored Phase I clinical trial (jRCT2031250472) of the alpha-emitting radiopharmaceutical af-001, which contains [²¹¹At]NaAt as its active pharmaceutical ingredient, in patients with differentiated thyroid cancer (papillary and follicular carcinoma).

This clinical trial is designed based on the results of an investigator-initiated Phase I study conducted at The University of Osaka, and consists of Part Ia and Part Ib.

In Part Ia, the maximum tolerated dose (MTD) of a single intravenous administration of af-001 will be determined in patients with differentiated thyroid cancer who are refractory to or intolerant of standard therapies. Part Ib will evaluate the efficacy and safety of multiple intravenous administrations of af-001 to determine the recommended dose for Phase II trials in patients with differentiated thyroid cancer who have not received prior radioactive iodine (RAI) therapy (RAI-naïve).

Part Ia of the study will be conducted at the National Cancer Center Hospital East (Principal Investigator: Dr. Makoto Tahara, Chief, Department of Head and Neck Medical Oncology), and Part Ib will be conducted at multiple sites in Japan.

The clinical development of af-001 will proceed with the goal of obtaining regulatory approval for use in patients with RAI-naïve differentiated thyroid cancer (papillary and follicular carcinoma). If clinical efficacy and safety are indicated in this patient population, af-001 is expected to contribute as a next-generation radiopharmaceutical and as a novel therapeutic option for differentiated thyroid cancer.

af-001 is manufactured under GMP for investigational products in collaboration with the Kobe City Medical Center General Hospital (Director: Dr. Yasuki Kihara; Chuo-ku, Kobe City, Hyogo), and promptly delivered to the National Cancer Center Hospital East after production.

(Reference: Prior release announced on PR Newswire, October 8, 2025)

Regarding the initiation of this study, Sunao Fujioka, CEO of Alpha Fusion Inc., commented as follows:

“Based on the achievements of the investigator-initiated Phase I study in patients refractory or intolerant to standard therapies, we expect to maximize the potential of af-001 by confirming its safety and efficacy in RAI-naïve patients. Alpha Fusion is fully committed to advancing the clinical development of af-001, with the ultimate goal of providing outpatient alpha-emitting radiopharmaceutical therapy to more patients with thyroid cancer. In addition, we are pursuing multiple research and development pipelines utilizing At-211, aiming to create innovative radiopharmaceuticals for various types of cancer.”

Background

RAI therapy is the standard treatment for differentiated thyroid cancer. However, in cases involving multiple metastases or insufficient therapeutic response despite clear iodine uptake, repeated RAI treatments may be required.

Moreover, due to radiation protection requirements in Japan, RAI therapy must be administered in shielded rooms, leading to hospitalization that imposes psychological stress on patients and financial burdens on hospitals. A survey in Japan reported an average waiting time of approximately 3.7 months, and 23% of facilities having a wait time exceeding six months (Survey Report on the Utilization of RI Therapy Rooms for Thyroid Cancer, 2022).

Given these challenges, there is a growing demand for patient-centric radiopharmaceuticals that can achieve potent tumor-reducing effects in an outpatient setting.

About At-211 (af-001)

af-001 is a radiopharmaceutical containing astatine-211 (At-211) as its active pharmaceutical ingredient. It is selectively taken up by differentiated thyroid cancer cells through the sodium/iodide symporter (NIS) and exerts a cytotoxic effect by emitting alpha particles.

At-211 emits alpha particles with higher energy than beta particles, inducing double-strand DNA breaks in cancer cell nuclei and leading to tumor regression.
Because alpha particles have a very limited range (approximately several tens of micrometers), af-001 can deliver strong therapeutic effects while minimizing damage to surrounding normal tissues. Consequently, substituting RAI with the limited-range alpha emitter af-001 may enable outpatient-based treatment.

With these unique characteristics, af-001 is being developed as a next-generation radiopharmaceutical and a novel treatment for differentiated thyroid cancer, offering both efficacy and safety.

Results of the Investigator-Initiated Clinical Trial and Positioning of the Company-Sponsored Trial

Prior to this company-sponsored trial, an investigator-initiated Phase I clinical trial (Alpha-T1 Trial) of [²¹¹At]NaAt, identical in composition to af-001, was conducted at The University of Osaka under the supervision of Dr. Tadashi Watabe, Principal Investigator (NCT05275946).

The study indicated the safety and tolerability of [²¹¹At]NaAt in patients with differentiated thyroid cancer refractory or intolerant to standard therapies. Additionally, the study reported a ≥50% reduction in thyroglobulin concentration (a tumor marker) and cases of disappearance of ¹³¹I uptake on imaging.

(Source: Watabe T. First-in-Human Study of [211At]NaAt as Targeted Alpha Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial). J Nucl Med. September 25, 2025.)

The present company-sponsored trial aims to evaluate the efficacy and safety of af-001 (identical in pharmaceutical ingredient to TAH-1005, [²¹¹At]NaAt) in RAI-naïve patients, with the objective of determining the recommended dose for subsequent Phase II studies.

About Alpha Fusion Inc.

Alpha Fusion Inc. is a biopharmaceutical company dedicated to the research and development of next-generation radiopharmaceutical therapies utilizing radioactive isotopes.

Through collaborative partnerships with domestic and international medical and research institutions, Alpha Fusion aims to create new treatment options in oncology and contribute to the advancement of precision radiopharmaceutical medicine.

Official website: https://alpha-fusion.com/en/

BOSTON, Oct. 31, 2025 /PRNewswire/ — Elevaris Medical Devices, a Contract Development and Manufacturing Organization for industry-leading multi-national healthcare companies, announced the appointment of its new Chief Engineering and Operations Officer, Salvador Montes.

“I have deep respect for the legacy Elevaris is leveraging and immense belief in our potential to deliver sustainable growth and customer satisfaction.”

Montes will be responsible for global engineering strategy and operations across the company’s facilities in the United States, the United Kingdom, and South Korea.

“Sal brings vast global experience and is incredibly pedigreed in execution, operational excellence, and continuous improvement,” said Richard Zrebiec, CEO of Elevaris Medical Devices. “We’re excited about the discipline, energy, and vision he brings as we continue to strengthen our engineering and manufacturing capabilities to catapult growth and deliver exceptional value to our customers.”

Montes brings to Elevaris more than 25 years of experience leading multi-site manufacturing and supply chain operations across the medical, aerospace, and consumer goods industries. His expertise spans Lean transformations, start-ups, mergers and acquisitions, and operational turnarounds; and, he has a proven record of building high-performance teams and driving sustainable results. He integrates Lean principles; Sales, Inventory, and Operations Planning; daily management systems, and policy deployment to link operational excellence directly with business and stakeholder outcomes.

“I am thrilled to join this team of development and engineering experts focused on applying such extensive manufacturing capabilities to deliver precision solutions to medical device customers,” Montes said. “I have deep respect for the legacy Elevaris is leveraging and immense belief in our potential to deliver sustainable growth and customer satisfaction.”

Montes is both Certified in Planning and Inventory Management by the American Production and Inventory Control Society and has operated under its Supply Chain Operations Reference Digital Standard, a digital, open-access, and comprehensive standard for evaluating and improving a company’s end-to-end supply chain operations. He also is a certified SCRUM Master, a coach and facilitator for the SCRUM framework intended to help people and teams solve complex problems via experimentation and feedback loops.

Montes is a graduate of Tecnologico de Monterrey and holds a degree in Industrial Engineering. He also has completed executive programs at McGill University, Northwestern’s Kellogg School of Management, and the Massachusetts Institute of Technology.

Beyond his academic achievements, Montes also has been a featured speaker at the American Manufacturing Summit and has been profiled in Hispanic Executive Magazine and BOSS Magazine.

About Elevaris Medical Devices: 

Elevaris Medical Devices is a Contract Development and Manufacturing Organization (CDMO) for industry-leading multi-national healthcare companies, medical device manufacturers, and emerging technology companies. It is one of the world’s leading manufacturers of made-to-spec procedural needles and specializes in the manufacture of precision micro-components, complex tubular components, and sub-assemblies. The company also distributes a wide range of complementary pharmaceutical products, surgical instruments, and medical supplies.

Elevaris Medical Devices has more than 300 employees across its locations in North America, the UK, and South Korea. For more information, visit elevarismedical.com.